Hypothesis

Escape genes on the X chromosome directly repress ileal Sgk1 expression, thereby limiting bile acid absorption and protecting against enterohepatic‑brain neurotoxicity. Females benefit from biallelic dosage of these repressors, while males, with a single X, exhibit higher Sgk1‑driven ASBT activity, increased bile acid accumulation in the hippocampus, and accelerated cognitive decline.

Mechanistic Rationale

1. X‑escape candidates – Genes such as Kdm6a (UTX) and Ddx3x escape X‑inhibition, encode chromatin modifiers, and are known to influence metabolic pathways (4).
2. Sgk1 regulation – Sgk1 transcription is modulated by histone acetylation at its promoter; KDM6A demethylates H3K27me3, fostering a repressive state, whereas loss of KDM6A activity leads to permissive chromatin and elevated Sgk1 (5).
3. Sex‑differential ileal expression – Single‑cell RNA‑seq of mouse ileum shows higher Kdm6a/Ddx3x transcript levels in XX enterocytes versus XY, correlating with lower Sgk1 mRNA (1).
4. Enterohepatic‑brain axis – Elevated ileal Sgk1 upregulates ASBT, increasing hepatic bile acid synthesis and circulating bile acids that cross the blood‑brain barrier, activate neuronal FXR, and trigger synaptic loss (5,6).
5. Cognitive resilience – Reduced bile acid influx preserves hippocampal synaptic density and mitigates age‑related cognitive decline, offering a mechanistic bridge between X‑dosage and the observed female longevity advantage (2).

Testable Predictions

• Prediction 1: In ileal epithelial cells, CRISPR‑mediated knockout of Kdm6a or Ddx3x in XX mice will increase Sgk1 expression, ASBT protein levels, and bile acid uptake to levels comparable to XY controls.
• Prediction 2: Pharmacological inhibition of Sgk1 (e.g., with GSK650394) in Kdm6a‑deficient XX mice will normalize bile acid absorption and rescue hippocampal synapse loss and cognitive performance.
• Prediction 3: XY mice engineered to carry an extra copy of Kdm6a (via autosomal transgene) will exhibit decreased ileal Sgk1, reduced bile acid brain accumulation, and improved lifespan‑matched cognitive scores relative to wild‑type XY.
• Prediction 4: Human ileal biopsies from post‑menopausal women will show higher KDM6A/DDX3X expression and lower SGK1 mRNA than age‑matched men; correlations will exist between SGK1 levels and serum bile acid concentrations.

Falsifiability

If manipulation of X‑escape genes fails to alter ileal Sgk1 expression or bile acid dynamics, or if altering Sgk1 does not modify cognitive outcomes despite changes in bile acid levels, the hypothesis would be refuted. Conversely, consistent directional changes across genetic, pharmacological, and human correlative approaches would support the proposed X‑chromosome‑centric control of the enterohepatic‑brain aging axis.

Implications

This framework shifts focus from gonadal hormones to sex‑chromosome‑encoded epigenetic regulators as primary modulators of a metabolic‑cognitive aging pathway. It suggests that therapies targeting Sgk1 or ASBT could be optimized by considering an individual’s X‑dosage status, potentially explaining sex‑specific responses to bile‑acid‑modulating interventions.